Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Psychiatry/Psychology
Disease Category: Post-Traumatic Stress Disorders
Trial Information
Evalation of the Efficacy of the NK1 Antagonist GR205171 in Post Traumatic Stress Disorder
This is a 10-week, double-blind, placebo-controlled trial of an
investigational medication in the treatment of post traumatic
stress disorder.
People with PTSD between the ages of 18 and 65 may be eligible for
this study. Potential participants receive a thorough psychiatric
and medical screening, and if found eligible, enter into the
10-week trial. Participants must be free of psychotropic
medications for at least 2 weeks prior to the beginning of the 10
weeks. There are weekly in-person visits throughout the study,
where study physicians evaluate the participant's progress and
monitor the occurrence of side effects, and participants have blood
drawn for safety lab tests.
Participants have the option of undergoing an MRI and lumbar
puncture both during the first 2 weeks of the study and at the end
of the 2 weeks.
Compensation Provided
Patient Inclusion/Exclusion Criteria:
Males and females between the ages of 18-65 with a primary
diagnosis of post-traumatic stress disorder
Current psychiatric medication, major unstable medical
conditions, hepatitis B,C, or any liver impairment, current or
recent substance abuse or dependence, pregnancy or lactation in
females, and current participation in structured psychotherapy
Douglas Brodman, Clinical Research Coordinator
Mount Sinai Medical Center
One Gustave L. Levy Place
New York, NY 10029
Phone: 212-241-6603
Fax: 212-241-3354
EMail: douglas.brodman@mssm.edu
View Google Map
If you would like to learn more about participating in this study, please send an e-mail message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these
trials.
